钠-葡萄糖协同转运蛋白2抑制剂与2型糖尿病心血管危险因素的研究进展  

SGLT-2 Inhibitors and Cardiovascular Risk Factors in Type 2 Diabetes Mellitus

作　　者：辛玉晶 刘昊凌[2] XIN Yujing;LIU Haoling(Graduate School of Harbin Medical University,Harbin 150000,Heilongjiang,China;Department of Endocrinology,The First Affiliated Hospital of Harbin Medical University,Harbin 150000,Heilongjiang,China)

机构地区：[1]哈尔滨医科大学研究生院,黑龙江哈尔滨150000 [2]哈尔滨医科大学附属第一医院内分泌科,黑龙江哈尔滨150000

出　　处：《心血管病学进展》2020年第3期235-238,共4页Advances in Cardiovascular Diseases

基　　金：哈尔滨医科大学研究生科研创新项目(YJSSJCX2018-16HYD)。

摘　　要：2型糖尿病的患病率在全球呈上升趋势,亚洲患者超过全球糖尿病患者数的一半。除了降糖作用外,钠-葡萄糖协同转运蛋白2抑制剂对多种危险因素包括血压、体重和肾脏功能等产生有利影响,并为2型糖尿病患者降低心血管疾病风险提供了机会。现对钠-葡萄糖协同转运蛋白2抑制剂治疗亚洲2型糖尿病的研究进展进行总结及分析。The incidence of type 2 diabetes mellitus has shown a global-dramatic rise.Furthermore,diabetes mellitus in Asia accounts for more than half of the global prevalence.In addition to lowering blood glucose,sodium-glucose cotransporter 2 inhibitors exert favourable effects on multiple risk factors including blood pressure,body weight and renal function.It provides an opportunity to reduce the risk of cardiovascular disease in patients with type 2 diabetes mellitus.This review summarized and analyzed the research progress of sodium-glucose cotransporter 2inhibitors in the treatment of Asian type 2 diabetes mellitus patients.

关 键 词：钠-葡萄糖协同转运蛋白2抑制剂 心血管疾病 2型糖尿病 

分 类 号：R587.2[医药卫生—内分泌] R54[医药卫生—内科学]